EGFR and non-small cell lung carcinoma: The activation of TP53 mutations affecting the apoptosis pathway may result in NSCLC patients with TP53 mutations (while EGFR-wild-type) not responding well to platinum-based chemotherapy (Molina-Vila et al., 2014; Dong et al., 2017).